Why is Hengrui Pharmaceuticals stock rallying today?

Jiangsu Hengrui Pharmaceuticals' stock surged 4.2% to HK$46.62 following the announcement of a significant licensing agreement with Danish pharmaceutical giant Novo Nordisk A/S. The deal gives Novo Nordisk exclusive worldwide rights, outside of Greater China, to develop, produce, and sell Hengrui's once-weekly oral GLP-1/GIP dual receptor agonist, HRS-1596, which targets obesity and diabetes.

The potential value of the agreement is up to $2.6 billion, starting with a $300 million upfront payment, along with milestone-based payments and royalties on future net sales in the licensed regions. This agreement highlights Hengrui's global out-licensing strategy, which has been a major factor driving the stock's re-rating. Hengrui has also been actively repurchasing its A-shares, with a buyback occurring in mid-September 2026.

Additionally, its non-oncology innovative drug revenues increased by approximately 74% year-on-year in the first half of 2026, indicating a growing commercial base beyond its traditional oncology focus. Despite gaining in Hong Kong and Chinese markets, Hengrui faced broader market challenges, as risk appetite was dampened by rising yields and tensions between the U.S. and Iran.